
        <!DOCTYPE html>
    <html lang="ja">
    <style>
    body
    {
        color: black;
        background-color: white;
    }
    div{
        font-size: 14px;
    }
    span
    {
        font-size: 18px;
    }
    #grad1{
        background: linear-gradient(transparent 60%,#99e4f1 30%);
        font-size: 18px;
        font-weight: bold;
    }
    #grad2{
        background: linear-gradient(transparent 60%,#fda1a1 30%);
        font-size: 18px;
        font-weight: bold;
    }

    </style>

    <head>
        <meta charset="UTF-8">
        <title>103-333</title>
    </head>

    <body>
        <h1>
        <a href="./103_332.html" rel="external" title="prev">≪</a>
        103-333
        <a href="./103_334.html" rel="external" title="next">≫</a>
        </h1>
        <div class='problem'>
            <p>
                <span id="grad1">　問題文　</span>
            </p>
            <p>
                <p>52歳男性。腰痛のためロキソプロフェンNaを服用している。全身倦怠感が続いたため受診した。検査の結果、薬物の長期服用による慢性肝疾患が疑われ入院した。肝機能に関する検査値は以下の通りである。ただし、(　)内は正常上限値とする。</p>
<p>AST 1,260IU/L (35)、ALT 1,330IU/L (35)、ALP 264IU/L (330)、T-Bil 0.9mg/dL (1.0)、γ-GTP 40IU/L (50)</p>
<p>薬物性肝障害の種類は以下のように分類される。</p>
<p><img alt="" class="alignnone size-full wp-image-3274" height="127.39999999999999" loading="lazy" sizes="(max-width: 765px) 100vw, 765px" src="data:;base64,iVBORw0KGgoAAAANSUhEUgAAAv0AAAC2BAMAAAC46C+hAAAAMFBMVEUjGRY2Ly1IRERZV1dqaWl5eXmJiYmYmJimp6e1trbCw8PQ0NHc3d3o6en09PT////eFM/IAAAd0UlEQVR42u2dfXwkVZnvK0kn6U6mU5kwDvgyTE8cxxneOnBHUV5MJ7RcEZ0O+NEF90KCzEZALwm4u3f8oKQZESPs0A0uSLNXOrCy+llWu70geM0uHUZddBXTvAgoGyoMsyis0DWdTtLVL/W9f1RVd1WmJy/TSSZ7rfMH9KTOy/N869SpU6fOrx4BOx3DJAs2A5u/zd9ONn+bv52ODX/BTscgiSX+8kKnSVz1frHqPVE8Ji3a/G3+Nn+bv83f5m/zt/nb/G3+Nn+bfyXj8hT0f+ZNh4oxoJBSU/xW0v6SvU8/pEIxVQV/VVLHy3/KfxqAQuKwzAXpn36htZOCl6vi/2ve0qqBkrfV+LGc/Gc2+AJQ3AWTA/kEPASf/NqpSj2gOLo/xGTgTQBmmgFeGh19eNebOWc1/Ou6m2YeGv12isIHoFijMdiwz5r1qpTSdFF8iOLo6OjOt6SRUDX845c/vWf45lMACAeq92M5+WdF+aqd/u46GLldcXTsbJUYfGxd5kQg5z50aSR89UUxuDRylysSOZvnBy+p/5ux29zVjD/O7ImZ7cM9IQgOQYN26FnhXEvWsV05cXfyh7HiZ+uDl/zKGZeq4T/rkm8YfbQZQN3SC1TpxzLzj6bCgPRnmS+KycSHIaiIyT8ffTCVd//gj9dFgl9MkHdG7v565Js14ySjLpIvVcV/e9Y7EyAMpHtL/OlwWLJOb/9vjvUdOwMUXXK06K6OP/97MkrWC5Bp/iFAdX4sJ39FlKOEgQc6k+8Xk4nzIayI1w8P+6J591XIofsTcH8L001EboBk1JVK/nKZ+Ku5Ev/8fY9b86YUcXcyAUWXfF9xXVX8X2Za3urv3gwQjM5crvM/ej+Wlb/Dp/GfafrE6zr/r7ZsgiD5dYGnnt136XOX03dX/5UNux2oD43c0Lh1bLQq/u3d3pkA4RTwe2jg3yvkVGKq4ljfkeCNHzfGr/9Yc1X8n778N3KUrAjknKjdiWr9WJH+r27bpOj8H2uIqdEgedfQX/X39/d/DrUw8YJ74tewZ/CS+uGR0ar7/wa/R+K82D0SDZyeALKt9eacxbq/e6mT11LMfq0+eMmt1fHPN1wzqfOPD8FBR6xKP5aZf4gwL8LUP/ynMf6s+8vu5iB5957MFyORjwO50UebH3sXEE+4SI4ux/iT4JV1Z2311/j9A2R/tz4WHzBnve60PxseHt67i3yzHC1Wx597N8d3+rtFyJ+Qonh2jxCtzo9l5n/N6OBDPfu2nnHFSY6OnRshrIgo3pvIu1/5zY7IN51Advhm5/CtQDjlZGyZ+OdO8urj/4zgZkpj9YcO4QQgf1bTqP/vBt+O0iKHClXynxl4eDx7Qwwe+PFOv9+vvKNKP5Z5/P/r4Z49w6H3hyP12vwn/FUxpYh7ybunbtkR+aZmZFaERyQ+jJNcfnn4M23MP9WOBNMtwC8fcSSID8D0F7wEE9+DTK8cIlYd/8lEMqC4/zaVvbF0oCo/lpW/Vw4RluCP8n23ismEH256TLxzt3glefdU/47IN5vhE37/eVv9/vZAYRP1+wq7q77/njsRjEIyUZ5/MuMGRmoSMNMCk089E+mJvA+ekOQ9iX/1VcX/CuR7/2/LlhC8loLZBBQ2Uff9o/ZjWef/nTr/ZM/NL2n8r1TE8O8G3kfe5blb408RQIJXE7xcx1igGv6urDezsd8Xhc9g4j8lArO9wKwb9iJf2hfpS6lnU5xZV3BUs/7wYj2yp9FxIyBv9ft9J8KrCV5wHrUfy7r+MKDzHxm762QxmeiG/66I4eLpzVLe/f7pCwaHzwVmt/X3/0U9fBlw5v68mvU3tSnrzQSIj/N8g5m/vNn4dUhEeRtyKEyYWQmy4oOJavjPOpGjihtADoE8BF+GrHjUfiwn/6mYHCUswV/I9zg1/u9UxDD7Q/vy7uLExMi/PLcLsu6JiYkGwO/313bVVcO/0JL1FsYBpl1Aado5MmT88kQpbkUOBQlDxu/vdrR2VsNfdSFHFZGQzj8E+P3djqP2Yzn5H3gzqfE/Vb7vITGZ8FHsVMQwcFa+Ofepft/5/ddod18atUVEJ0hV8FcCWS+gpig2AqWRxWdM/QedwGBKDgWf84AKWVEb/456/Hcg79kj4jXxT5EVj9qP5eR/638ICcIJcjE5mnP4/a1kH79FDI+OPlanNAPxKMCs3v+fmpiYaJx4qaEK/pl/+cTJo6OjP3wX1Jr455q1/58unJkCglF5IDixkcLExMQL7gnrw8FS+3/No74dSkvWVR5/npqYeMF91H4sI381qn4QgglU5FjOC7vJEgw8LQjC2flNQDwGMNPQ39/fAJ/q19L40fP/DYO37RkeHr4VPCnUWmPBM2rJOhKaGQ9KKab1Bj9fFf9DZ5EXhCZIbvX7fQPV+rGc/R+AJ9HmOPr7CCXFxIR+bb6eAshHgcertU0GeJyXjH//GPiA3v1PtmbNpuAXy0MDRvMp+NHwOBwch9kVGHWq5L9KaR6LcitHY3WT/f7X5m/zt/nb/G3+Nn+bv83f5m/z/1Pkb2vhbP2dPf7Y/G3+Nn+bv83f5m/zt/n/afHP3gffTmhHfq69bCtEyX/f5r86/GebwNepHdF3GykOsk02/9Xhr4gUnHdrRyajZBIwvQlF5Mb/GvxTx4S/umz882Io0zk1AH/p9/u2+jvWweQn+3c37K6Rjta4VLX8D3phtrUmAIRrW2ta52zCPCB0khbaAMhU2iBSLj/bWtN+5lx7fnr6haqnDjw1XsPF62OQaa0ZAkXYIqwXpDm4rzwulha8ZFprtcp8FXa7zJ4EdAnHA11C27tvtB4tF7fwT59X57pDKhw3TopM60kABP954kX3xITROUz1JmtaazwugOmy3LBw3obEEpBkLEiKe8cBT43EfqHN4H9nE5B2A3Qlkl6l0ZqbMRc8oVfRWuFsm8qn3ezfBHBJ2d5T6UkUhCiFEw0XVU8vkPQCmXcWawkPAepZ5TOemHUx2QiT+ok51HJ4qwfqgWIt2n/z6yXg1VjpcKm4hX/xNbHwDp4IOxIwOPKNKKC2/uqtPe7nxw3jTPUORtPu/AaAwpbSCdgvTTcvBUnSyw826X/OdX0JQBUCWnGN/4X1QEYEiuuQA9xpzc2hLSnS+t+M3UE86qk1uly5PBmRvANg/wlGxikvyQBtJ4LXcDEXbwHkAJAcx4HiBbjjJKPIYIo20h1SqVXZq//Idgkf1H8+JKQwdos5YCQAKG2lE1Aqbh1/psRXH/FtvfdtKbJN8rc2SJAVsk2O/r6ScaZ6d5AReUICyLUbNZ9B0bEUJHKAnL6n7dG36TOvrS5IG+OP2tllZFZCyAGmJWvu9MiA0ViuWd+YstdxX86jzd9M5cmIoH3r7gGDptyM7OWkBhP/bKbJ4H8POOAyAG76mF7EF8JDeixQcnEkQQzgeeEGdVDfIx3yxcz8Za3mDcYGrlJxK/+k87aUHPpjCq5LJEPPOL7HK31Z0YUcNYwr11sMkBHJRrGcACFB7VKQyAEdSXHvB40r5dT1Upl/LhSOGZl1Ktbc6elmrbGhN64TXEojfOgOhwRprYi5fEaEGiwnQLmcsQDenoSJv1Jvaqm8ld04AY9Iai3p2Sat1Vn1O61CNDzEoy8IISjoG4RD4V4L/81YTkCpuJV/0PHeDb6tngQHL/z8T7730R4htCecFWv9vjJ/U70lKqaa70oVHEtBIgd0JIMfK9XlDQfK/Kelyd7D+Ztyp4vHaY11CB2hQZ7oxCPEAF2tbi6fEck1zKEJPTG8T3eW+X9PFVKV+Kt91xrOOkmrW1JpgCmhzjkrFo4jrknCtX3BOWmyxTL+6Lfo1xq0blMqbuX/vnUfECdDQfIfpa6/35H/aHEobOn/lnrN/Mlu0DvkdNNSkMgBHckfzih9UsA77Srzf5XpzYfzN+VOEwylAZ4buJiklK8nvgmgqJE2l8+I6v2nlbrzLv0KbQRv1lnmH6InVok/at+Q/mjUS5qRoTRA8fxpb9FNvHdG6/l9EkCW6SYT/9ePM67W1xp1o/XiFv75k8WsmIwG+U9wggsgnBUbImGDv6VeC3/9fgojQ0tBIgfUOz6kzUSuu0A30qu2SiX+3yXXdDh/U+40U5u0wa7QTDi1W0hp8/Gs5qm5fKa2/SPl6YBHu5E8MQReTpdK/KOMBCry1+cdqO+BNJl1+hA7llBaZnwt+ky7IwWgaHc1rbDQvjVaqiPp1YzWi1v4T4+KWUfHTg9Ard9v4h/Ss1rqrdj/C8cvCYlc236BUcUP9Vuql3hnif9F7e31FfiXc6fJ16eNuUwfP+/QCR9ax9zylv6i9391h9Zir8E/19buaZm3/2eGIE2xLm1MOWbEwlf0OWheO0X3t7cLKdP4U0ql/q8Xt/B/MicqnVfsehDK/T+YFV2aBkGcW2+l8Z8D0SUhkc2aqte7xjX+M06DvxqAnlQl/kbuNPT9H+3Ki9FeehpVOwaYW97M3xj/X42RwstMs7d0iZNzzTv+fxaVNAS1mXCuibS39JwZ11wMwUi0Av/S+G8Ut/CXFDfq8TcDUB+J6PzdtX6fwd9Sr8mf0vxHPUszbrFILPx13YoX1bNf558LQThGRoRpaU72ouHKK+0AtEmF8tPeYIN+rzeVN/EvTUAvQfXiRW0z8VcdWksHK85/lF7SpCG9XutUpzJWegD+mZAw+E8GwAFqwFRFef5jFJ+z/uMmc9rU2Vb+LeeQe7zMv1xvmX95/j8d4sBSkJSAtre3t7e3D2n8iZ+hWzQ9DpO9ZETYazpdptxpUGq1G/9Xn9NVMep3OhwaCEv5Mv8SfiXAf/TihbDB/58AXwo5AJ8y8y9NmJ5JcSVpyGuPEj3fvcynP4r86CJBu0Ry45BpAQdMD5SrMM3/jeJz1p/dXCypnjNf1saf/CnQN+OKRO6p1dZ/rPWW/DE9//4t6ieXgkSuoOn0wmytbtGYdmdPu/mZs3T3sqQxCboB4p1pQa/tr/pvNY6ayxtTBNPz76Gt/tZQwQ0ZnX9hMzAYIunl4XWlW675+bfL39XI5Dj0AOTr8OiAn+v/os73CWDWSbGWfMd4qQrT82+p+Fz+D98IB125nX6/3+/3f1jnH4lo/C31lqc8pvWfNn+XcylISkDLPVptBtr1FSnhXaiemv/VWrNFaIH9rTXeObkPCA54BiA+nj1MoWgpr6/iWdZ/RgRB+LVHCFDU+XtqxpkRajOtNVuETgpb9HWs8vqPKghCU7q1Fl4ByK8j2FmhVfoEb5fQ1lpHl7CxdKsxMpSKW/kXvvR9ALPM6d+K46WlUmu9pFtrTpnTck4QhHVLQJJprTls8XCLcArsP6r158QxWX/Or+X3j1Ugsd//2u9/bf42f5u/zd/mb/O3+dv8bf42f5u/zd/mb/O3+dv8bf42f5u/zd/mb/O3+dv8bf7/P/MvAuSNN7ZPJlaevwTwqP6Hwg2rwl9ds/ynd3b5/V31wB7g/uaV5/8J/wa/v7UXZkOQa02sBn/fwFrlD9Nw6B1AeED78P7Kjz+9sD4GSgPQl1oN/oda1i7/DNpuu3gnzIqrwT9AoQHI1wGDqzL+lPRE+c8I702tsf4vMZgAgtFsatrRllp5/pcx2wxkXdxOT9dpq8Df0BNlPRekHli3tvhno7QB9JAVhJozV6H/f51DXmBaJCgIxw2tNI2Snmjq9daPA561xT8f0EQsO0F9cVXGn0cYCQFTAXgzuPLjT0lPlBaaAI42lOdKzf83TW0GcALKqvA/JJ0OehiE8MrzL+mJ8jUSQHJgbfHvH4kCNN22WvxnrnEByN9NrAr/uXqi4NDa4j92HIDq3gy5VeFfqOkEmHwaGFkN/hY9Ea3ja4v/VDNA0bmZ4oR7NfjTkQBI3gQTSWnl+Vv1RK82sLb497RJgCr0ZgWhYTX4T9ecCjBZT1AQBlaehkVPNLsaLS6F/0HX084UIIQmExnBufL8Vd+3Wm8HZKfajE9Y+dmISU/0xheEC9fW82+hPVHs2Pg4eKLyJX0nrex6jAyw/2SerflcirSL+ltqV3jJSbToiWY/dVVsba0/qNfdCLOCMEAwVPDUSc+v+PPv749PwaDQQNbJfuHc4rUrzr+CnmjN8L/5doDnTwAltfK2yZD9SAooXhGC+1aJRnV6ohXlX5RYzSTDxKo2aL//qjT/tPnb/G3+Nn+bv83f5m/zt/nb/G3+Nn+bv83f5m/zt/nb/G3+Nn+bv83f5n+s+Q+sNv987NjzP3obloV/XtK/RQvKEfgXE6ip5eP/Eryl/5xKLGjUyvBfFhuWhX+2kenjdUuOsF2sWJMq1EnLxj95ImPnaj9/cmSjpnasJP/kiYydU60NS+VfMf6O4tb26AMPgzmA0HWl2D+N1u+AaykjCIK0AP+K8Y/kodKXc68G1G7gOmEDpmhDipvpw4Us6pXHxeZ1sWKG5bXB7PVS+VeMv6O4ybq1i/HTWAII4ZEKWyQAJzTo1+vukoMZv//DC/X/ivGP5BDygJoC1M2A4omhf9C/FG1IcTMjUj67ufNBD140n4uWDH+vD5lHtgFpKTbw1bleL5V/xfg7SgtZN9dLaF/xNQUQwgfxgM6/kb0SQO6izxvj5iLGn4rxj+QQ8lD2VCA7BGTivRihP0rRhkSmvcXjjcr+9W0x0IMXzeeiOcMDb9d/HNmG4vFLsIGbTpnr9VL5V4y/o4iZH4m5mhDMDmEJIITPiP3jyl3mzNdo2wfVr2zX+kR6Yf6V4x/J0QeTofgJQFoCXs1sNvsui5pRD3sP1Gn3o+LeD+ix0kLzKVpES4afGl/pnseGA3Xji7Wh9NX1dDX8K8XfURwdG8WRyw0a5gBCPiP2T21XvfMHu4y6ntwQWyT/yvGP5K2tPbdtSAHfBviu0mTxfbNmVOvHt2hDnRErTA9eNJ+L5Qwl/PPYsG9LbLE2lD96XwX/yvF3FJGs82yAB8EaQMhnxP5xka8/qVxZbn0CmHqk5toF+FeOfyRHiV8cA7gQ4DK13nLtD2hGJbtv16aB60231KxzgS6mZzBCVcxrw2duX6wNpvNp9nqJ/CvH31FEI0bq2WANIOTjDU0k6SLfaJoYX/FpAPnC365Pzc+/cvwjOUp8CPQbjtrJRSbftWhDikjSCPj24MbyBH2sdwH+WobZMv55bLhx8TYcLF1OZq+XyL9y/B1FJCsCFDrBGkDI175VO/8u8uW9yy+8W9vNqUBwYH7+leMfyVHiCYCZEJALMRIzfDeiDSmingXg9TO+bIzl71nART2DxzRrWQ4biuVhz+z1EvlXjr9T4j8dZU4AIZ9R2sRf/cZ7y85NeufnXzn+Ucn3V1LAdFu7p9d07XMYf4rX6wHzMkMLuKhnMPf/ZbGh3P/NXi+Rf+X4Ozp/SQvpYAkgZOKvNOuf07jpc2bI4rz8jxD/SI4STlCEuwEOwnRLBd9HEqbH/0c1/z873+c1RFOG8vi/TDb89IQKXi+df4X4O4rIkyKFEF/T+ZcDCJn4/76ZYgjg5fKTYCeTnfPyP0L8IzmqDiZ4EU7RxgeUJs33y8y+BxPMlnvxm6AHL5rPxXKGEq95bZhNLdoGY/5j9npp/I8Qf0dpuvIeEWWIU2FOAKES/8abr2omNwTm4C2TLQSj8/I/Qvwjec/5wQTfIR8A+B+g1oMPst6y7027exJkxoFZrUXQgxfN56Ipg3EC5rUhM744G0wnwOz10vhXjr/z4sV10aybgx/KBZgbQEi/jWV31/xPxcXBD1mrnHHnN84//6wc/+gW30YpHFXPS2ViQEHU7pceqdATMu5zL15cFw2HGJsjGOvydzXO66I5g/78O58NxENLsEF7/jV7vST+R4i/M1Wf0ALvZBLMCSCkrUeBUnsfBUEQ1ln7P19pi87L/wjxj8I7UowJgjD+DHqLB4TjrxPaWoWUEW1oqj7BmCAInZb+rwqC9lmBI7lozfD3KRa0oXNxNpjWf8xeL8f6cyEG/Gj469L+IxceAn4+PLwkMfORLZoFCsPDf8Me5jOqcM/wrUt66bCU9edZ9AaqsmFZ33/ds7zv5hbx/mvX8r8NXHLaVW2L9vvfY+aizd/mb/O3+dv8bf42f5u/zd/mb/P/k+Qv2OkYpDJ/Ox2rZPO3+dv87WTzt/nbyeZv819k0jbKFBIc4QVbVuIP0iLqKS5NnLQPdZ/+c5FqsyU1UIhS+Jb2Mx9bo/w1IcXTQ1D4cqG2oG3UeOIyAK4lGoE3ANlV2qwxP56aVKFu8a+GhaixwUNZLP+lqJ8UBwW9/iPpulab/wGhk0xrbbkL7ff7uxx+/4VAX8KV1fgntd0l7d2O8E6/JwojA8jRgmUHiEmlowhbhPWaEKeiOAmL2qms+8k1gIufA0z92lMHnhrLHsZFq58wC4tmW2vaz0wBTG8q1f+TtOC1On6M+v+YCyatHWhGWyxJvDLkenU8DyBrvXFHtnlE4iag65b+vvM/U2/pXGWVTuadxVrCQ6CLkyooBU1qp7LuJ3NCf7+j39MLPExBiFI40XKGF1A/WZJJWJR2s38TwOQnS/VfzWTjYY4fC/6Htkj6trz7Qxb+ua3dO2vf7e8YMvHPDMQl9kLR8ceJ5L6Jl80VmVQ6yXEcKF4dTyNPDx3WbFntZNL9JHc9NeGcmEgBn4a2E8HS/RdSP1lSWVhERiTvAAj+84Rev7qZdIe0gEpkVfin48a2yJ7NFv4HBiQoctFpGv+3gO0HUvGd/naYacjnR/Y9arl4TSqde8ABl4EmTlI95xzWbFntZNL99A0kfux86Vq0jfcnNczhv6D6yXytlIVFZEQQALX1V299Sas/O0R6LLAm+E8362b8TJsS/DSk8ffE7uzvv6L3Wn38uWgctt+L1v+TrvSOhn6fpVubVTrlMbm2q975zDsOb9aidtJv5UUh2h7u392Ipjbz9iTm8F9Y/VS+VkzCoowINUBWyDY5tPrTEunZpjXBv9hmNWOyd0YsXA57CE9M6DFq5A1+fy9s/wedf78rfak4J2aLWaVT5u8i37Bdu07Ky7Jz1U46/5m+6HvCWuyZtATepzut/BdSP5kbMAuLMiK5BuCVvqzo0ur/NqTVLam1wJ/wkMUMOTTj6HIAhPXYRKXxf/tsb/wMv4dCpyt9tcPvsV7wJpWOhX9jhTmGVe2k8/+JHN0W9neLaGozb9Zp5b8I9VN5NDQJizKiev9pwJ5wVqzV6r8Q0owMrQn+U+65/PWXRWF/jc/Kv9gU/+34s9JMypW+ek7/t6h0LPwrBVawqp10/tfK0W16/z8b8HK6ZOG/sPrJNBqahEWZ2vaPpKA4FDb6f9ELaTLr1gT/gqMy/+JLNObftPCnIf7vN/oC4Epf7Yr0mYtZVDoL8reqncq6h23hyN2irjbzEu81819Q/WROZmGRIWYgnBUbIneLmq4rTbFuTfBn8E7z/bfEX9nW7+j3RU38t/21My5t3YfB3zzrs6h0zPxL4iRtq7hXH0rMaicrf7euNvMy0+y1jFkLqJ9MDViERXP4uzVdVxqCd64J/un15vlnmb97wjkRlMz9P3haXLoZULXxR1K2my54k0rHzP/3zXDjYdMfi9rJ4D8Z3RZGcaOpzbyobV6ujJn4z69+so6GZWFRiX8wK7pQ3Jquq+z4seaf13LdEZrDX8Slj/EG/98Rn7jpcii60lc5/B6JYEn2YlHplPk33nxVM3xsLh6r2sngn4xuC/q73WhqMy+EvUyXQmEtqH4yj4ZmYZGJv7vW3+3WtGVlx4/t+oMEPYeN//lzNP56XEx5AL4h4aQwuOGXtQmKrvQ1vbwRI23Qsah0SppYXZyUnytMn6N20nU/JKPbHkT9RzgVKLgh46UoRPUWNrNo9ZNVWJR2l/i3nIP6j5q2bHJ8juPHaP3NoV/u+rrsTt/WLoe/qyZFVlSdz9bCF/x+3wa/X/DizAkbxwk6KLjkCyKRu+pRjAYsKh0KW4Q2KIuT6uZcc1a1k6H7YSzqiEQiPb25AKgeIUDRC32Bcgvzq5+sDZSERfrnfYC+GVckEunpzcQg3VprcXytrD+X76m5gaKzcBmmxa23c0EKcrvIu+QLIpHIvajvn7+2IeAXw8PfX1zb8agjEolEYhnz4vAT0YUaWLT6SeMfiT2z5t+/6On2I72euT2/Egu3f0g9rq2BrxCOfytq52nPfxX+xyjds8L177L5/2kkm7/N3+ZvJ5u/zd9Ox4D//wOa2GGr5fSr8wAAAABJRU5ErkJggg==" width="535.5"/></p>
<p>この患者の治療に推奨する薬物はどれか。2つ選べ。</p>
<ol><li>タウリン</li><li>ウルソデオキシコール酸</li><li>グリチルリチン酸</li><li>ソホスブビル</li><li>リバビリン</li></ol>    
            </p>
        </div>
        <hr>

        <input type="button" value="check ans" onclick="toggle_switch()"/>
        
        <div id='toggle'>
        <div class='answer'>
            <p>
                <span id="grad2">　解答　　</span>
            </p>
            <p>
            2, 3
            </p>
        </div>
        <div class='description'>
            <p>
                <span id="grad2">　解説　　</span>
            </p>
            <p><span style="font-weight: 400;">ALT ＞ 2N( = 70 ) かつ ALP ≦ N (330) なので、</span><span style="font-weight: 400;">肝細胞障害型とわかります。</span></p>
<p><span style="font-weight: 400;">選択肢 1 ですが<br/></span><span style="font-weight: 400;">タウリンは、</span><span style="font-weight: 400;">肝・循環機能改善剤です。</span><span style="font-weight: 400;">高ビリルビン血症における肝機能改善に用いられます。</span><span style="font-weight: 400;">ビリルビンは基準値内です。</span><span style="font-weight: 400;">よって、選択肢 1 は誤りです。</span></p>
<p><span style="font-weight: 400;">選択肢 2,3 は、正しい記述です。</span></p>
<p><span style="font-weight: 400;">選択肢 4,5 ですが<br/></span><span style="font-weight: 400;">これらの薬剤は C 型肝炎治療薬です。</span><span style="font-weight: 400;">薬物性肝障害には用いられません。</span><span style="font-weight: 400;">よって、選択肢 4,5 は誤りです。</span></p>
<p><span style="font-weight: 400;">以上より、正解は 2,3 です。</span></p>
<p><span style="font-weight: 400;">ちなみに、</span><span style="font-weight: 400;">ソホスブビルは</span><span style="font-weight: 400;">核酸型NS5Bポリメラーゼ阻害剤です。</span><span style="font-weight: 400;">プロドラッグです。</span><span style="font-weight: 400;">肝細胞内でカルボキシルエステラーゼ</span><span style="font-weight: 400;">（CES1）などによる代謝を受け</span><span style="font-weight: 400;">活性代謝物ウリジンアナログ-3リン酸</span><span style="font-weight: 400;">となり薬効を発揮します。</span></p>
<p><span style="font-weight: 400;">リバビリンは、</span><span style="font-weight: 400;">インターフェロンとの併用で</span><span style="font-weight: 400;">効果を発揮する抗ウイルス薬です。</span></p>
            </p>
        </div>
        </div>
    </body>
    <script>
    document.getElementById("toggle").style.display="none";
    function toggle_switch(){
        var x = document.getElementById("toggle");
        if (x.style.display=="block"){
            x.style.display="none";
        }
        else{
            x.style.display="block";
        }
    }
    </script>
    